Brief: AbbVie Announces European Commission Approval Of RINVOQ (Upadacitinib)
22/09/2026 07:41
BRIEF-AbbVie Announces European Commission Approval Of RINVOQ (Upadacitinib) Sept 22 (Reuters) - AbbVie Inc. ABBV.N:
ABBVIE ANNOUNCES EUROPEAN COMMISSION APPROVAL OF RINVOQ® (UPADACITINIB) FOR THE TREATMENT OF CHILDREN WITH ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS
ABBVIE - RINVOQ APPROVED IN EU FOR PJIA IN PATIENTS AGED TWO YEARS AND OLDER
Source text: ID:nPn4Vqq9sa
Further company coverage: ABBV.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AbbVie
See all newsBrief: Abbvie Reaches Agreement With The Pan-Canadian Pharmaceutical Alliance (Pcpa) For Elahere® In Platinum-Resistant Ovarian Cancer
Eli Lilly hits record high as healthcare stocks rally
Nvidia-backed Iambic Therapeutics tumbles below IPO price
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Abbvie Says Risankizumab In Ulcerative Colitis Shows Clinical Remission Rates Of 54.0%-73.1% At Week 96